Background: This study aimed to compare the efficacy and safety of S-1 and capecitabine in
patients with metastatic colorectal carcinoma (mCRC). Methods: Eligible prospective clinical …

Objectives: To compare the 2-year overall survival (OS) rate and safety between patients
using S-1 and capecitabine in the first-treatment of metastatic colorectal cancer in the real …

We previously reported the results of a multicenter, open-label phase III trial (ClinicalTrials.
gov: NCT01918852) in which 161 metastatic colorectal cancer patients, in whom first-line …

Background Hand–foot syndrome (HFS) is a common side-effect of capecitabine. S-1 is an
oral fluoropyrimidine with comparable efficacy to capecitabine in gastrointestinal cancers but …

3640 Background: Hand-foot syndrome (HFS) is a common side effect of capecitabine. S-1
is an oral fluoropyrimidine with comparable efficacy to capecitabine in gastrointestinal …

Background S-1 is an oral fluoropyrimidine that is increasingly used in Western countries for
the treatment of metastatic colorectal cancer (mCRC). We conducted a non-inferiority meta …

Introduction The oral fluoropyrimidine S-1 has shown comparable efficacy to capecitabine in
Asian and some Western studies on metastatic colorectal cancer. S-1 is associated with a …

Background We report updated progression-free survival (PFS) and overall survival (OS)
data from a trial that compared capecitabine plus oxaliplatin (CapeOX) versus S-1 plus …

Introduction: Intravenous administration of fluoropyrimidine-based chemotherapy has been
the cornerstone of treatment in metastatic colorectal cancer (mCRC) for decades. The …

Summary Background Capecitabine plus oxaliplatin (CapeOX) is one of the reference
doublet cytotoxic chemotherapy treatments for patients with metastatic colorectal cancer. We …